Activated ClpP kills persisters and eradicates a chronic biofilm infection

Nature

Volumn 503, Issue 7476, 2013, Pages 365-370

  Conlon, B P ^a   Nakayasu, E S ^b,d   Fleck, L E ^a   Lafleur, M D ^c   Isabella, V M ^a   Coleman, K ^c   Leonard, S N ^a   Smith, R D ^b   Adkins, J N ^b   Lewis, K ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c Arietis Corp   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLDEPSIPEPTIDE 4; CIPROFLOXACIN; ELONGATION FACTOR TU; ENDOPEPTIDASE CLP; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; PYRUVATE KINASE; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTICS; BIOFILM; DORMANCY; ENZYME ACTIVITY; INFECTIVITY; INHIBITION; PATHOGEN; PROBABILITY; PROTEIN;

ANIMAL EXPERIMENT; ANTIBIOTIC THERAPY; ARTICLE; BIOFILM; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOFILMS; DEPSIPEPTIDES; DRUG RESISTANCE, BACTERIAL; ENZYME ACTIVATION; FEMALE; MICE; MICROBIAL VIABILITY; PROTEOLYSIS; PROTEOMICS; RIFAMPIN; SERINE ENDOPEPTIDASES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALIA; STAPHYLOCOCCUS AUREUS;

EID: 84888019629     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12790     Document Type: Article

References (50)

1. Alekshun, M. N. & Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037-1050 (2007).
2. Lewis, K. Persister cells. Annu. Rev. Microbiol. 64, 357-372 (2010).
3. Keren, I., Shah, D., Spoering, A., Kaldalu, N. & Lewis, K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 186, 8172-8180 (2004).
4. Keren, I., Wu, Y., Inocencio, J., Mulcahy, L. R. & Lewis, K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339, 1213-1216 (2013).
5. Bigger, J. W. Treatment of staphylococcal infections with penicillin. Lancet 244, 497-500 (1944).
6. Spoering, A. L.&Lewis, K. Biofilmsand planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183, 6746-6751 (2001).
7. Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: A common cause of persistent infections. Science 284, 1318-1322 (1999).
8. Kostakioti, M., Hadjifrangiskou, M. & Hultgren, S. J. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb. Perspect. Med. 3, a010306 (2013).
9. Maisonneuve, E., Shakespeare, L. J., Jorgensen, M. G. & Gerdes, K. Bacterial persistence by RNA endonucleases. Proc. Natl Acad. Sci. USA 108, 13206-13211 (2011).
10. Moyed, H. S.&Bertrand, K. P. hipA, anewly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J. Bacteriol. 155, 768-775 (1983).
11. Germain, E., Castro-Roa, D., Zenkin, N. & Gerdes, K. Molecular mechanism of bacterial persistence by HipA. Mol. Cell 52, 248-254 (2013).
12. Correia, F. F. et al. Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. J. Bacteriol. 188, 8360-8367 (2006).
13. Harrison, J. J. et al.Thechromosomaltoxin gene yafQ is a determinant ofmultidrug tolerance for Escherichia coli growing in a biofilm. Antimicrob. Agents Chemother. 53, 2253-2258 (2009).
14. Maisonneuve, E., Castro-Camargo, M. & Gerdes, K. (p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity. Cell 154, 1140-1150 (2013).
15. Dörr, T., Vulić, M. & Lewis, K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8, e1000317 (2010).
16. Unoson, C. & Wagner, E. A small SOS-induced toxin is targeted against the inner membrane in Escherichia coli. Mol. Microbiol. 70, 258-270 (2008).
17. Gurnev, P. A., Ortenberg, R.,Dorr, T., Lewis, K.&Bezrukov, S. M.Persister-promoting bacterial toxin TisB produces anion-selective pores in planar lipid bilayers. FEBS Lett. 586, 2529-2534 (2012).
18. Lewis, K. Platforms for antibiotic discovery. Nature Rev. Drug Discov. 12, 371-387 (2013).
19. Brötz-Oesterhelt, H. et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nature Med. 11, 1082-1087 (2005).
20. Gottesman, S., Roche, E., Zhou, Y. & Sauer, R. T. The ClpXP and ClpAP proteases degrade proteins with carboxy-terminal peptide tails added by the SsrA-tagging system. Genes Dev. 12, 1338-1347 (1998).
21. Li, D. H. et al. Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: A model for the ClpX/ClpA-bound state of ClpP. Chem. Biol. 17, 959-969 (2010).
22. Lee, B. G. et al. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. Nature Struct. Mol. Biol. 17, 471-478 (2010).
23. Kirstein, J. et al. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol. Med. 1, 37-49 (2009).
24. Michel, K. H. & Kastner, R. E. A54556 antibiotics and process for production thereof. US patent 4,492 650 (1985).
25. Sass, P. et al. Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ. Proc. Natl Acad. Sci. USA 108, 17474-17479 (2011).
26. Michalik, S. et al. Proteolysisduring long-termglucose starvation in Staphylococcus aureus COL. Proteomics 9, 4468-4477 (2009).
27. Buske, P. J. & Levin, P. A. A flexible C-terminal linker is required for proper FtsZ assembly in vitro andcytokinetic ring formationin vivo. Mol. Microbiol.89, 249-263 (2013).
28. Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13-18 (2004).
29. Johnson, P. J. & Levin, B. R. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet. 9, e1003123 (2013).
30. Frees, D., Qazi, S. N., Hill, P. J. & Ingmer, H. Alternative roles of ClpX and ClpP in Staphylococcus aureus stress tolerance and virulence. Mol. Microbiol. 48, 1565-1578 (2003).
31. Hussain, M., Hastings, J. G. & White, P. J. A chemically defined medium for slime production by coagulase-negative staphylococci. J. Med. Microbiol. 34, 143-147 (1991).
32. Stryjewski, M. E. & Chambers, H. F. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46 (Suppl 5), S368-S377 (2008).
33. Gillaspy, A. F. et al. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect. Immun. 63, 3373-3380 (1995).
34. Miyazaki, M. et al. Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 55, 1819-1820 (2011).
35. Lewis, K. Antibiotics: recover the lost art of drug discovery. Nature 485, 439-440 (2012).
36. Hung, C. et al. Escherichia coli biofilms have an organized and complex extracellular matrix structure. mBio 4, e00645-13 (2013).
37. Vlamakis, H., Chai, Y., Beauregard, P., Losick, R. & Kolter, R. Sticking together: building a biofilm the Bacillus subtilis way. Nature Rev. Microbiol. 11, 157-168 (2013).
38. LaFleur, M. D., Qi, Q. & Lewis, K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob. Agents Chemother. 54, 39-44 (2010).
39. Mulcahy, L. R., Burns, J. L., Lory, S. & Lewis, K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 192, 6191-6199 (2010).
40. Mwangi, M. M. et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl Acad. Sci. USA 104, 9451-9456 (2007).
41. Levin, B. R.&Rozen, D. E.Non-inherited antibiotic resistance.Nature Rev. Microbiol. 4, 556-562 (2006).
42. Howden, B. P. et al. Evolution ofmultidrug resistance during Staphylococcus aureus infection involvesmutation of the essential two component regulator WalKR. PLoS Pathog. 7, e1002359 (2011).
43. Leung, E. et al. Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease. Chem. Biol. 18, 1167-1178 (2011).
44. Wang, Y. et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics 11, 2019-2026 (2011).
45. Livesay, E. A. et al. Fully automated four-column capillary LC-MS system for maximizingthroughput in proteomic analyses. Anal.Chem. 80,294-302(2008).
46. Mayampurath, A. M. et al. DeconMSn: a software tool for accurate parent ion monoisotopic mass determination for tandem mass spectra. Bioinformatics 24, 1021-1023 (2008).
47. Kim, S. et al. The generating function of CID, ETD, and CID/ETD pairs of tandem mass spectra: applications to database search. Mol. Cell Proteomics 9, 2840-2852 (2010).
48. Monroe, M. E., Shaw, J. L., Daly, D. S., Adkins, J. N.&Smith, R. D.MASIC: a software program for fast quantitation and flexible visualization of chromatographic profiles from detected LC-MS(/MS) features. Comput. Biol. Chem. 32, 215-217 (2008).
49. Zuluaga, A. F. et al.Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6, 55 (2006).
50. Blaser, J. In-vitromodelfor simultaneous simulationof the serumkinetics of twodrugs with different half-lives. J. Antimicrob.Chemother.15(Suppl A),125-130(1985).